PRE Overview

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

Wall Street analysts forecast PRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prenetics Global Ltd revenue for the last quarter amounts to 36.56M USD, increased 457.12

Prenetics Global Ltd. EPS for the last quarter amounts to -0.47 USD, decreased -63.28

Prenetics Global Ltd (PRE) has 98 emplpoyees as of June 01 2026.

Today PRE has the market capitalization of 361.73M USD.